Gain Therapeutics Ownership 2024 | Who Owns Gain Therapeutics Now?

Overview Forecast RevenueFinancials Chart

Institutional Ownership

4.56%

Insider Ownership

5.09%

Retail Ownership

90.34%

Institutional Holders

8.00

Gain Therapeutics Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
TIMELO INVESTMENT MANAGEMENT INC.	3.37%	0.44%	605,288	605,288	100.00%	774,769	Jun 30, 2024
DME CAPITAL MANAGEMENT, LP	3.15%	0.04%	566,130	-	-	724,646	Jun 30, 2024
ALYESKA INVESTMENT GROUP, L.P.	2.50%	0.00%	450,000	450,000	100.00%	576,000	Jun 30, 2024
HOHIMER WEALTH MANAGEMENT, LLC	1.84%	0.10%	330,000	330,000	100.00%	422,400	Jun 30, 2024
GEODE CAPITAL MANAGEMENT, LLC	1.02%	-	183,736	6,645	3.75%	235,217	Jun 30, 2024
VANGUARD GROUP INC	0.81%	-	145,217	25,853	21.66%	185,878	Jun 30, 2024
CABLE CAR CAPITAL LLC	0.81%	0.20%	145,000	145,000	100.00%	185,600	Jun 30, 2024
RENAISSANCE TECHNOLOGIES LLC	0.66%	0.00%	118,700	72,000	154.18%	151,936	Jun 30, 2024
CM MANAGEMENT, LLC	0.50%	0.11%	90,000	-	-	115,200	Jun 30, 2024
BLACKROCK INC.	0.47%	-	84,620	9,222	12.23%	108,313	Jun 30, 2024
WARBERG ASSET MANAGEMENT LLC	0.29%	0.01%	51,600	51,600	100.00%	65,532	Jun 30, 2024
NORTHERN TRUST CORP	0.25%	-	44,944	-1,542	-3.32%	57,529,000	Jun 30, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC	0.22%	0.00%	40,000	10,000	33.33%	51,200	Jun 30, 2024
PRELUDE CAPITAL MANAGEMENT, LLC	0.20%	0.00%	35,820	-	-	45,850	Jun 30, 2024
STATE STREET CORP	0.19%	-	34,437	3,600	11.67%	44,079,000	Jun 30, 2024
VIRTU FINANCIAL LLC	0.15%	0.00%	27,356	27,356	100.00%	35,000	Jun 30, 2024
MILLENNIUM MANAGEMENT LLC	0.13%	-	23,373	-21,043	-47.38%	29,917	Jun 30, 2024
UBS GROUP AG	0.06%	-	11,422	2,749	31.70%	14,620	Jun 30, 2024
GILBERT & COOK, INC.	0.06%	0.00%	10,000	10,000	100.00%	12,800	Jun 30, 2024
SIMPLEX TRADING, LLC	0.05%	-	9,059	-8,924	-49.62%	11,000	Jun 30, 2024

Gain Therapeutics's largest institutional shareholder is TIMELO INVESTMENT MANAGEMENT INC., holding 3.37% of the company's total share outstanding, currently valued at $774.77K. The top 10 institutional shareholders own together 15.12% of the company.

Institutional Shareholders by % of Total Assets

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
TIMELO INVESTMENT MANAGEMENT INC.	3.37%	0.44%	605,288	605,288	100.00%	774,769	Jun 30, 2024
CABLE CAR CAPITAL LLC	0.81%	0.20%	145,000	145,000	100.00%	185,600	Jun 30, 2024
CM MANAGEMENT, LLC	0.50%	0.11%	90,000	-	-	115,200	Jun 30, 2024
HOHIMER WEALTH MANAGEMENT, LLC	1.84%	0.10%	330,000	330,000	100.00%	422,400	Jun 30, 2024
DME CAPITAL MANAGEMENT, LP	3.15%	0.04%	566,130	-	-	724,646	Jun 30, 2024
WARBERG ASSET MANAGEMENT LLC	0.29%	0.01%	51,600	51,600	100.00%	65,532	Jun 30, 2024
ALYESKA INVESTMENT GROUP, L.P.	2.50%	0.00%	450,000	450,000	100.00%	576,000	Jun 30, 2024
PRELUDE CAPITAL MANAGEMENT, LLC	0.20%	0.00%	35,820	-	-	45,850	Jun 30, 2024
VIRTU FINANCIAL LLC	0.15%	0.00%	27,356	27,356	100.00%	35,000	Jun 30, 2024
GILBERT & COOK, INC.	0.06%	0.00%	10,000	10,000	100.00%	12,800	Jun 30, 2024
CREEKMUR ASSET MANAGEMENT LLC	0.02%	0.00%	4,440	-	-	5,683	Jun 30, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC	0.22%	0.00%	40,000	10,000	33.33%	51,200	Jun 30, 2024
RENAISSANCE TECHNOLOGIES LLC	0.66%	0.00%	118,700	72,000	154.18%	151,936	Jun 30, 2024
TOWER RESEARCH CAPITAL LLC (TRC)	0.01%	-	1,729	-2,903	-62.67%	2,213	Jun 30, 2024
GROUP ONE TRADING, L.P.	0.04%	-	7,401	5,400	269.87%	9,473,000	Jun 30, 2024
GEODE CAPITAL MANAGEMENT, LLC	1.02%	-	183,736	6,645	3.75%	235,217	Jun 30, 2024
MILLENNIUM MANAGEMENT LLC	0.13%	-	23,373	-21,043	-47.38%	29,917	Jun 30, 2024
JONES FINANCIAL COMPANIES LLLP	0.04%	-	7,000	7,000	100.00%	8,960	Jun 30, 2024
NORTHERN TRUST CORP	0.25%	-	44,944	-1,542	-3.32%	57,529,000	Jun 30, 2024
SIMPLEX TRADING, LLC	0.05%	-	9,059	-8,924	-49.62%	11,000	Jun 30, 2024

The largest Gain Therapeutics shareholder by % of total assets is TIMELO INVESTMENT MANAGEMENT INC.. The company owns 605.29K shares of Gain Therapeutics (GANX), representing 0.44% of its total assets.

Institutional Buyers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
TIMELO INVESTMENT MANAGEMENT INC.	3.37%	0.44%	605,288	605,288	100.00%	774,769	Jun 30, 2024
ALYESKA INVESTMENT GROUP, L.P.	2.50%	0.00%	450,000	450,000	100.00%	576,000	Jun 30, 2024
HOHIMER WEALTH MANAGEMENT, LLC	1.84%	0.10%	330,000	330,000	100.00%	422,400	Jun 30, 2024
CABLE CAR CAPITAL LLC	0.81%	0.20%	145,000	145,000	100.00%	185,600	Jun 30, 2024
RENAISSANCE TECHNOLOGIES LLC	0.66%	0.00%	118,700	72,000	154.18%	151,936	Jun 30, 2024
WARBERG ASSET MANAGEMENT LLC	0.29%	0.01%	51,600	51,600	100.00%	65,532	Jun 30, 2024
VIRTU FINANCIAL LLC	0.15%	0.00%	27,356	27,356	100.00%	35,000	Jun 30, 2024
VANGUARD GROUP INC	0.81%	-	145,217	25,853	21.66%	185,878	Jun 30, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC	0.22%	0.00%	40,000	10,000	33.33%	51,200	Jun 30, 2024
GILBERT & COOK, INC.	0.06%	0.00%	10,000	10,000	100.00%	12,800	Jun 30, 2024
BLACKROCK INC.	0.47%	-	84,620	9,222	12.23%	108,313	Jun 30, 2024
JONES FINANCIAL COMPANIES LLLP	0.04%	-	7,000	7,000	100.00%	8,960	Jun 30, 2024
GEODE CAPITAL MANAGEMENT, LLC	1.02%	-	183,736	6,645	3.75%	235,217	Jun 30, 2024
GROUP ONE TRADING, L.P.	0.04%	-	7,401	5,400	269.87%	9,473,000	Jun 30, 2024
STATE STREET CORP	0.19%	-	34,437	3,600	11.67%	44,079,000	Jun 30, 2024
UBS GROUP AG	0.06%	-	11,422	2,749	31.70%	14,620	Jun 30, 2024
MORGAN STANLEY	0.02%	-	3,300	500	17.86%	4,224	Jun 30, 2024
BANK OF AMERICA CORP /DE/	0.02%	-	3,500	125	3.70%	4,480	Jun 30, 2024
CREEKMUR ASSET MANAGEMENT LLC	0.02%	0.00%	4,440	-	-	5,683	Jun 30, 2024
PRELUDE CAPITAL MANAGEMENT, LLC	0.20%	0.00%	35,820	-	-	45,850	Jun 30, 2024

As of Jun 30 2024, Gain Therapeutics's largest institutional buyer is TIMELO INVESTMENT MANAGEMENT INC.. The company purchased 605.29K stocks of GANX, valued at $774.77K.

Institutional Sellers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
RAYMOND JAMES & ASSOCIATES	-	-	-	-260,019	-100.00%	-	Jun 30, 2024
ROYAL BANK OF CANADA	-	-	-	-248,500	-100.00%	-	Jun 30, 2024
MILLENNIUM MANAGEMENT LLC	0.13%	-	23,373	-21,043	-47.38%	29,917	Jun 30, 2024
SIMPLEX TRADING, LLC	0.05%	-	9,059	-8,924	-49.62%	11,000	Jun 30, 2024
TOWER RESEARCH CAPITAL LLC (TRC)	0.01%	-	1,729	-2,903	-62.67%	2,213	Jun 30, 2024
NORTHERN TRUST CORP	0.25%	-	44,944	-1,542	-3.32%	57,529,000	Jun 30, 2024
WELLS FARGO & COMPANY/MN	0.01%	-	2,650	-1,106	-29.45%	3,392	Jun 30, 2024
HM PAYSON & CO	-	-	-	-1,000	-100.00%	-	Jun 30, 2024
NEWEDGE ADVISORS, LLC	-	-	-	-225	-100.00%	-	Jun 30, 2024
CM MANAGEMENT, LLC	0.50%	0.11%	90,000	-	-	115,200	Jun 30, 2024
DME CAPITAL MANAGEMENT, LP	3.15%	0.04%	566,130	-	-	724,646	Jun 30, 2024
PRELUDE CAPITAL MANAGEMENT, LLC	0.20%	0.00%	35,820	-	-	45,850	Jun 30, 2024
CREEKMUR ASSET MANAGEMENT LLC	0.02%	0.00%	4,440	-	-	5,683	Jun 30, 2024
BANK OF AMERICA CORP /DE/	0.02%	-	3,500	125	3.70%	4,480	Jun 30, 2024
MORGAN STANLEY	0.02%	-	3,300	500	17.86%	4,224	Jun 30, 2024
UBS GROUP AG	0.06%	-	11,422	2,749	31.70%	14,620	Jun 30, 2024
STATE STREET CORP	0.19%	-	34,437	3,600	11.67%	44,079,000	Jun 30, 2024
GROUP ONE TRADING, L.P.	0.04%	-	7,401	5,400	269.87%	9,473,000	Jun 30, 2024
GEODE CAPITAL MANAGEMENT, LLC	1.02%	-	183,736	6,645	3.75%	235,217	Jun 30, 2024
JONES FINANCIAL COMPANIES LLLP	0.04%	-	7,000	7,000	100.00%	8,960	Jun 30, 2024

As of Jun 30 2024, Gain Therapeutics's biggest institutional seller is RAYMOND JAMES & ASSOCIATES. The company sold -0.26M shares of GANX, valued at -.

Institutional New positions

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
TIMELO INVESTMENT MANAGEMENT INC.	3.37%	0.44%	605,288	605,288	100.00%	774,769	Jun 30, 2024
ALYESKA INVESTMENT GROUP, L.P.	2.50%	0.00%	450,000	450,000	100.00%	576,000	Jun 30, 2024
HOHIMER WEALTH MANAGEMENT, LLC	1.84%	0.10%	330,000	330,000	100.00%	422,400	Jun 30, 2024
CABLE CAR CAPITAL LLC	0.81%	0.20%	145,000	145,000	100.00%	185,600	Jun 30, 2024
WARBERG ASSET MANAGEMENT LLC	0.29%	0.01%	51,600	51,600	100.00%	65,532	Jun 30, 2024
VIRTU FINANCIAL LLC	0.15%	0.00%	27,356	27,356	100.00%	35,000	Jun 30, 2024
GILBERT & COOK, INC.	0.06%	0.00%	10,000	10,000	100.00%	12,800	Jun 30, 2024
JONES FINANCIAL COMPANIES LLLP	0.04%	-	7,000	7,000	100.00%	8,960	Jun 30, 2024

Gain Therapeutics's largest new institutional shareholder by number of shares is TIMELO INVESTMENT MANAGEMENT INC., purchased 605.29K shares, valued at $774.77K, as of undefined.

Institutional Sold Out

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
RAYMOND JAMES & ASSOCIATES	-	-	-	-260,019	-100.00%	-	Jun 30, 2024
ROYAL BANK OF CANADA	-	-	-	-248,500	-100.00%	-	Jun 30, 2024
HM PAYSON & CO	-	-	-	-1,000	-100.00%	-	Jun 30, 2024
NEWEDGE ADVISORS, LLC	-	-	-	-225	-100.00%	-	Jun 30, 2024

Gain Therapeutics's largest sold out institutional shareholder by shares sold is RAYMOND JAMES & ASSOCIATES, sold -0.26M shares, valued at -, as of undefined.

Gain Therapeutics Mutual Fund Holders

Name	% Total Assets	Total Shares	Change Amount	Change %	Date
BRIDGEWAY FUNDS INC	0.01%	30,000	-16,100	-34.92%	Mar 28, 2024
FIDELITY CONCORD STREET TRUST	0.00%	148,748	-389	-0.26%	Feb 29, 2024
VANGUARD INDEX FUNDS	0.00%	109,849	-47,891	-30.36%	Mar 31, 2024
SCHWAB CAPITAL TRUST	0.00%	7,043	-	-	Jan 31, 2024
DFA INVESTMENT DIMENSIONS GROUP INC	0.00%	13,531	-	-	Jan 31, 2024
USAA MUTUAL FUNDS TRUST	0.00%	1,102	-	-	Jan 31, 2024
Dimensional ETF Trust	0.00%	933	-	-	Jan 31, 2024
EQ ADVISORS TRUST	0.00%	2,374	449	23.32%	Mar 31, 2024
iSHARES TRUST	0.00%	29,923	5,419	22.11%	Mar 31, 2024
JOHN HANCOCK VARIABLE INSURANCE TRUST	0.00%	238	148	164.44%	Mar 31, 2024

Gain Therapeutics's largest mutual fund holder by % of total assets is "BRIDGEWAY FUNDS INC", owning 30.00K shares, compromising 0.01% of its total assets.

Gain Therapeutics Institutional Ownership Trends

Institutional Holdings Trend

Date	Holdings	Change %
30 Jun, 24	8	-73.33%
31 Mar, 24	30	15.38%
31 Dec, 23	26	-
30 Sep, 23	26	-3.70%
30 Jun, 23	27	12.50%
31 Mar, 23	24	14.29%
31 Dec, 22	21	-4.55%
30 Sep, 22	22	37.50%
30 Jun, 22	16	-
31 Mar, 22	16	-11.11%
31 Dec, 21	18	38.46%
30 Sep, 21	13	8.33%
30 Jun, 21	12	-
31 Mar, 21	12	-

As of 30 Jun 24, 8 institutions are holding Gain Therapeutics's shares, representing a decrease of -73.33% compared to the previous quarter.

Shares Outstanding Trend

Date	Shares Outstanding	Change %
30 Jun, 24	820,451	-56.07%
31 Mar, 24	1,867,615	20.86%
31 Dec, 23	1,545,247	1.96%
30 Sep, 23	1,515,523	19.55%
30 Jun, 23	1,267,722	10.29%
31 Mar, 23	1,149,488	-4.75%
31 Dec, 22	1,206,763	-0.55%
30 Sep, 22	1,213,396	12.87%
30 Jun, 22	1,075,072	-7.46%
31 Mar, 22	1,161,738	10.04%
31 Dec, 21	1,055,755	18.28%
30 Sep, 21	892,606	-0.18%
30 Jun, 21	894,199	-11.13%
31 Mar, 21	1,006,151	-

Gain Therapeutics (GANX) has 820.45K shares outstanding as of 30 Jun 24, down -56.07% compared to the previous quarter.

Institutional Ownership Trend

Date	Ownership %	Change %
30 Jun, 24	4.56%	3.44%
31 Mar, 24	11.52%	7.79%
31 Dec, 23	12.17%	8.13%
30 Sep, 23	12.23%	10.84%
30 Jun, 23	10.62%	11.45%
31 Mar, 23	9.63%	9.34%
31 Dec, 22	10.16%	9.74%
30 Sep, 22	10.21%	12.48%
30 Jun, 22	9.05%	9.47%
31 Mar, 22	9.78%	9.06%
31 Dec, 21	10.39%	18.39%
30 Sep, 21	7.52%	13.26%
30 Jun, 21	7.53%	10.49%
31 Mar, 21	8.47%	-

As of 30 Jun 24, Gain Therapeutics is held by 4.56% institutional shareholders, representing a 3.44% growth compared to 31 Mar 24.

Institutional Increased Positions Trend

Date	Increased Positions	Change %
30 Jun, 24	6	-60.00%
31 Mar, 24	15	36.36%
31 Dec, 23	11	-8.33%
30 Sep, 23	12	-14.29%
30 Jun, 23	14	55.56%
31 Mar, 23	9	12.50%
31 Dec, 22	8	-38.46%
30 Sep, 22	13	44.44%
30 Jun, 22	9	28.57%
31 Mar, 22	7	-36.36%
31 Dec, 21	11	83.33%
30 Sep, 21	6	-14.29%
30 Jun, 21	7	-41.67%
31 Mar, 21	12	-

6 institutional shareholders have increased their position in GANX stock as of 30 Jun 24 compared to 15 in the previous quarter (a -60.00% decrease).

Institutional Reduced Positions Trend

Date	Reduced Positions	Change %
30 Jun, 24	1	-85.71%
31 Mar, 24	7	16.67%
31 Dec, 23	6	20.00%
30 Sep, 23	5	25.00%
30 Jun, 23	4	-33.33%
31 Mar, 23	6	-
31 Dec, 22	6	50.00%
30 Sep, 22	4	33.33%
30 Jun, 22	3	-40.00%
31 Mar, 22	5	400.00%
31 Dec, 21	1	-
30 Sep, 21	1	-50.00%
30 Jun, 21	2	-
31 Mar, 21	-	-

1 institutional shareholders have reduced their position in GANX stock as of 30 Jun 24 compared to 7 in the previous quarter (a -85.71% decrease).

All Institutional Ownership Trend Data

Date	Holdings	Change %	Shares Outstanding	Change %	Ownership %	Change %	Increased Positions	Change %	Reduced Positions	Change %
30 Jun, 24	8	-73.33%	820,451	-56.07%	4.56%	3.44%	6	-60.00%	1	-85.71%
31 Mar, 24	30	15.38%	1,867,615	20.86%	11.52%	7.79%	15	36.36%	7	16.67%
31 Dec, 23	26	-	1,545,247	1.96%	12.17%	8.13%	11	-8.33%	6	20.00%
30 Sep, 23	26	-3.70%	1,515,523	19.55%	12.23%	10.84%	12	-14.29%	5	25.00%
30 Jun, 23	27	12.50%	1,267,722	10.29%	10.62%	11.45%	14	55.56%	4	-33.33%
31 Mar, 23	24	14.29%	1,149,488	-4.75%	9.63%	9.34%	9	12.50%	6	-
31 Dec, 22	21	-4.55%	1,206,763	-0.55%	10.16%	9.74%	8	-38.46%	6	50.00%
30 Sep, 22	22	37.50%	1,213,396	12.87%	10.21%	12.48%	13	44.44%	4	33.33%
30 Jun, 22	16	-	1,075,072	-7.46%	9.05%	9.47%	9	28.57%	3	-40.00%
31 Mar, 22	16	-11.11%	1,161,738	10.04%	9.78%	9.06%	7	-36.36%	5	400.00%
31 Dec, 21	18	38.46%	1,055,755	18.28%	10.39%	18.39%	11	83.33%	1	-
30 Sep, 21	13	8.33%	892,606	-0.18%	7.52%	13.26%	6	-14.29%	1	-50.00%
30 Jun, 21	12	-	894,199	-11.13%	7.53%	10.49%	7	-41.67%	2	-
31 Mar, 21	12	-	1,006,151	-	8.47%	-	12	-	-	-

Gain Therapeutics Insider Shareholders Trades

Open Market Insider Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Aug 12, 2024	Mack Gene	officer	CFO and Interim CEO	P-Purchase	Buy	14,400	$1.01	$14.54K	14,400
Aug 12, 2024	Islam Khalid	director, officer	Executive Chairman	P-Purchase	Buy	50,000	$1.00	$49.94K	50,000
Jul 01, 2024	RICHMAN ERIC I	director	-	P-Purchase	Buy	12,000	$1.21	$14.52K	289,629
Jul 01, 2024	RICHMAN ERIC I	director	-	P-Purchase	Buy	5,000	$1.23	$6.15K	277,629
Apr 01, 2024	Riley Jeffrey Scott	director	-	P-Purchase	Buy	30,000	$3.86	$115.77K	30,000

Open Market Insider Buys

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Aug 12, 2024	Mack Gene	officer	CFO and Interim CEO	P-Purchase	Buy	14,400	$1.01	$14.54K	14,400
Aug 12, 2024	Islam Khalid	director, officer	Executive Chairman	P-Purchase	Buy	50,000	$1.00	$49.94K	50,000
Jul 01, 2024	RICHMAN ERIC I	director	-	P-Purchase	Buy	12,000	$1.21	$14.52K	289,629
Jul 01, 2024	RICHMAN ERIC I	director	-	P-Purchase	Buy	5,000	$1.23	$6.15K	277,629
Apr 01, 2024	Riley Jeffrey Scott	director	-	P-Purchase	Buy	30,000	$3.86	$115.77K	30,000

Insider Sells

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Mar 28, 2024	Alder Matthias	director, officer	Chief Executive Officer	M-Exempt	Sell	18,750	-	-	56,250
Mar 28, 2024	Alder Matthias	director, officer	Chief Executive Officer	F-InKind	Sell	6,085	$4.06	$24.71K	21,140
Mar 28, 2024	Alder Matthias	director, officer	Chief Executive Officer	M-Exempt	Sell	825	-	-	8,250

All Insider Owners Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Aug 12, 2024	Mack Gene	officer	CFO and Interim CEO	P-Purchase	Buy	14,400	$1.01	$14.54K	14,400
Aug 12, 2024	Islam Khalid	director, officer	Executive Chairman	P-Purchase	Buy	50,000	$1.00	$49.94K	50,000
Jul 01, 2024	RICHMAN ERIC I	director	-	P-Purchase	Buy	12,000	$1.21	$14.52K	289,629
Jul 01, 2024	RICHMAN ERIC I	director	-	P-Purchase	Buy	5,000	$1.23	$6.15K	277,629
Jun 26, 2024	Islam Khalid	director	-	A-Award	Buy	15,000	$1.29	$19.35K	15,000
Jun 26, 2024	Melincoff Gwen A	director	-	A-Award	Buy	15,000	$1.29	$19.35K	15,000
Jun 26, 2024	HASLER HANS PETER	director	-	A-Award	Buy	15,000	$1.29	$19.35K	15,000
Jun 26, 2024	Nicaise Claude	director	-	A-Award	Buy	15,000	$1.29	$19.35K	15,000
Jun 26, 2024	RICHMAN ERIC I	director	-	A-Award	Buy	15,000	$1.29	$19.35K	15,000
Jun 26, 2024	GOLDSTEIN DOV A MD	director	-	A-Award	Buy	15,000	$1.29	$19.35K	15,000
Jun 26, 2024	Riley Jeffrey Scott	director	-	A-Award	Buy	15,000	$1.29	$19.35K	15,000
Apr 08, 2024	Mack Gene	officer	Chief Financial Officer	A-Award	Buy	200,000	$3.56	$712.00K	200,000
Apr 08, 2024	Mack Gene	officer	-		Buy	-	-	-	-
Apr 01, 2024	Riley Jeffrey Scott	director	-	P-Purchase	Buy	30,000	$3.86	$115.77K	30,000
Mar 28, 2024	Alder Matthias	director, officer	Chief Executive Officer	M-Exempt	Sell	18,750	-	-	56,250
Mar 28, 2024	Alder Matthias	director, officer	Chief Executive Officer	M-Exempt	Buy	637	-	-	27,225
Mar 28, 2024	Alder Matthias	director, officer	Chief Executive Officer	M-Exempt	Buy	825	-	-	26,588
Mar 28, 2024	Alder Matthias	director, officer	Chief Executive Officer	M-Exempt	Buy	18,750	-	-	25,763
Mar 28, 2024	Alder Matthias	director, officer	Chief Executive Officer	F-InKind	Sell	6,085	$4.06	$24.71K	21,140
Mar 28, 2024	Alder Matthias	director, officer	Chief Executive Officer	M-Exempt	Sell	825	-	-	8,250

The last insider sell of Gain Therapeutics's stock was made by Alder Matthias on Mar 28 2024, selling 18,750 shares at - per share (valued at -). The last insider buy of GANX was made by Mack Gene on Aug 12 2024, buying 14,400 shares at $1.01 per share (worth $14.54K).

Gain Therapeutics Insider Ownership Trends

All Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q3 2024	2	-	-
Q2 2024	8	-	-
Q1 2024	6	4	150.00%
Q4 2023	2	4	50.00%
Q3 2023	3	3	100.00%
Q2 2023	8	-	-
Q1 2023	5	-	-
Q4 2022	-	1	-
Q3 2022	7	-	-
Q2 2022	5	-	-
Q4 2021	1	-	-
Q3 2021	2	-	-
Q1 2021	-	10	-

2 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Gain Therapeutics's insiders, as of Q3 2024.

Open Market Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q3 2024	2	-	-
Q2 2024	-	-	-
Q1 2024	1	-	-
Q4 2023	-	2	-
Q3 2023	-	-	-
Q2 2023	-	-	-
Q1 2023	-	-	-
Q4 2022	-	-	-
Q3 2022	-	-	-
Q2 2022	5	-	-
Q4 2021	-	-	-
Q3 2021	1	-	-
Q1 2021	-	-	-

As of Q3 2024, Insider owners conducted 2 open market buy trades and 0 open market sell trades of Gain Therapeutics's stocks.

Gain Therapeutics Peer Ownership

Ticker	Company
CUE	Cue Biopharma, Inc.
CYT	Cyteir Therapeutics, Inc.
INBX	Inhibrx Biosciences, Inc.
CSBR	Champions Oncology, Inc.
BIVI	BioVie Inc.
LTRN	Lantern Pharma Inc.
MNOV	MediciNova, Inc.
NAMS	NewAmsterdam Pharma Company N.V.
TFFP	TFF Pharmaceuticals, Inc.
INAB	IN8bio, Inc.
ANEB	Anebulo Pharmaceuticals, Inc.
MOLN	Molecular Partners AG
LIFE	aTyr Pharma, Inc.
CELC	Celcuity Inc.
MACK	Merrimack Pharmaceuticals, Inc.
ELVN	Enliven Therapeutics, Inc.
ELYM	Eliem Therapeutics, Inc.

GANX Ownership FAQ

Who Owns Gain Therapeutics?

Gain Therapeutics is owned by institutional shareholders (4.56%), insiders (5.09%), and public (90.34%). The largest institutional shareholder of Gain Therapeutics is TIMELO INVESTMENT MANAGEMENT INC. (3.37% of total shares) and the top mutual fund owner is BRIDGEWAY FUNDS INC (0.01% of total shares).

Who are the major institutional shareholders of Gain Therapeutics?

Gain Therapeutics's major institutional shareholders are TIMELO INVESTMENT MANAGEMENT INC., DME CAPITAL MANAGEMENT, LP, ALYESKA INVESTMENT GROUP, L.P., HOHIMER WEALTH MANAGEMENT, LLC, and GEODE CAPITAL MANAGEMENT, LLC. The top five shareholders own together 11.88% of the company's share outstanding.

How many Gain Therapeutics shareholders are there?

As of Jun 2024, there are 8 institutional shareholders of Gain Therapeutics.

What percentage of Gain Therapeutics is owned by TIMELO INVESTMENT MANAGEMENT INC?

TIMELO INVESTMENT MANAGEMENT INC owns 605.29K shares of Gain Therapeutics, representing 3.37% of the company's total shares outstanding, valued at $774.77K (as of Jun 2024).

What percentage of Gain Therapeutics is owned by DME CAPITAL MANAGEMENT, LP?

As of Jun 2024, DME CAPITAL MANAGEMENT, LP holds 566.13K shares of Gain Therapeutics (GANX), compromising 3.15% of the company, valued at $724.65K.

What percentage of Gain Therapeutics is owned by ALYESKA INVESTMENT GROUP, L.P?

ALYESKA INVESTMENT GROUP, L.P is the third largest holder of Gain Therapeutics. The company owns 450K of the company's shares outstanding (worth $576K).